About Vir Biotechnology
Vir Biotechnology is a company based in San Francisco (United States) founded in 2017 by Klaus Frueh. Vir Biotechnology has raised $216 million across 4 funding rounds from investors including Gates Foundation, Arch Venture Partners and GSK. The company has 408 employees as of December 31, 2024. Vir Biotechnology has completed 2 acquisitions, including Agenovir and TomegaVax. Vir Biotechnology offers products and services including Antibody Platform and PRO-XTEN™ Masking Technology. Vir Biotechnology operates in a competitive market with competitors including BeiGene, Serum Institute of India, Vaxcyte, BioNTech and Biological E, among others.
- Headquarter San Francisco, United States
- Employees 408 as on 31 Dec, 2024
- Founders Klaus Frueh
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vir Biotechnology, Inc.
-
Annual Revenue
$74.2 M (USD)-13.9as on Dec 31, 2024
-
Net Profit
-$521.96 M (USD)15.14as on Dec 31, 2024
-
EBITDA
-$508.86 M (USD)20.68as on Dec 31, 2024
-
Total Equity Funding
$216 M (USD)
in 4 rounds
-
Latest Funding Round
$32.44 M (USD), Post-IPO
May 06, 2020
-
Investors
Gates Foundation
& 2 more
-
Employee Count
408
as on Dec 31, 2024
-
Investments & Acquisitions
Agenovir
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vir Biotechnology
Vir Biotechnology is a publicly listed company on the NASDAQ with ticker symbol VIR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vir Biotechnology
Vir Biotechnology offers a comprehensive portfolio of products and services, including Antibody Platform and PRO-XTEN™ Masking Technology.
Platform for discovering and optimizing antibody-based medicines for diseases.
Technology for masking and releasing treatments in infectious diseases and cancer.
People of Vir Biotechnology
Unlock access to complete
Unlock access to complete
Leadership Team
45 people
Operations Team
11 people
Software Development Team
8 people
Senior Team
8 people
Finance and Accounting
6 people
Product Management Team
3 people
Human Resources and Administration
2 people
Sales and Marketing
2 people
Unlock access to complete
Funding Insights of Vir Biotechnology
Vir Biotechnology has successfully raised a total of $216M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $32.44 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vir Biotechnology
Vir Biotechnology has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Arch Venture Partners and GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
Locked | Locked | Locked | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked |
Investor details for Vir Biotechnology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vir Biotechnology
Vir Biotechnology has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Agenovir and TomegaVax.
Investment portfolio details for Vir Biotechnology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Antiviral therapeutics are developed using nuclease-based technologies for infectious diseases.
|
Locked | Locked | 2014 | Locked | |
|
Developing cytomegalovirus-vector based vaccines for viral infections
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Vir Biotechnology
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Vir Biotechnology
Detailed financials for Vir Biotechnology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vir Biotechnology Comparisons
Peer comparison for Vir Biotechnology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vir Biotechnology
Vir Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Serum Institute of India, Vaxcyte, BioNTech and Biological E, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
Detailed competitors of Vir Biotechnology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vir Biotechnology
Complete news archive for Vir Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vir Biotechnology
Vir Biotechnology was founded in 2017.
Vir Biotechnology is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
George Scangos is the current CEO of Vir Biotechnology.
Vir Biotechnology is a funded company, having raised a total of $216M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Vir Biotechnology is 408.
Annual revenue of Vir Biotechnology is $74.2M as on Dec 31, 2024.
Developer of therapeutics for the treatment of infectious diseases. The companys approach is focused on immune programming to manipulate pathogen-host interactions. The company has developed drugs for Covid-19, HBV, HIV, and influenza-A.
Vir Biotechnology offers Antibody Platform and PRO-XTEN™ Masking Technology.
Yes, Vir Biotechnology is publicly traded on NASDAQ under the ticker symbol VIR.
Vir Biotechnology has 3 investors. Key investors include Gates Foundation, Arch Venture Partners, and GSK.
The ticker symbol of Vir Biotechnology is VIR on NASDAQ.